Prevalence of the UGT1A1*6 (c.211G>A) Polymorphism and Prediction of Irinotecan Toxicity in Iranian Populations of Different Ethnicities
Authors:
- Reyhaneh ShakibiRSReyhaneh Shakibi
- Behnam KamalidehghanBKBehnam Kamalidehghan
- Fatemeh AhmadipourFAFatemeh Ahmadipour
- Goh Yong MengGMGoh Yong Meng
- Massoud HoushmandMHMassoud Houshmand
- 1 January 2014
- journal article
- Published by S. Karger AG in Chemotherapy
- Vol. 60 (5-6) , 279-287
Abstract
Background: Pharmacogenetic studies on irinotecan treatment in patients with metastatic colorectal cancer have indicated that genetic polymorphisms in UGT1A1*6 can lead to decreased enzyme activity and accumulation of the toxic metabolite SN-38. Here, we compared the prevalence of UGT1A1*6 in an Iranian population of different ethnicities with those of other populations. Materials and Methods: A total of 300 healthy people of different ethnic groups including Persian, Azari, Lure, Kurdish, Arab, Baluch and Caspian in the Iranian population were enrolled. Genotyping of the UGT1A1*6 alleles (G/G, A/G, A/A) was performed by polymerase chain reaction-restriction fragment length polymorphism and direct genomic DNA sequencing. Result: The most predictive genotype among the Iranian ethnic groups, especially Persian, was the G/G genotype (wild-type genotype). The frequency of the A/G genotype among the Persian, Azari, Lure, Kurdish, Arab, Baluch and Caspian ethnicities were 15.69% (n = 27), 11.11% (n = 8), 5.88% (n = 1), 9.09% (n = 1), 10% (n = 1), 20% (n = 1) and 0% (n = 0), respectively. Only one person with Persian ethnicity was homozygous for the mutation in UGT1A1*6 (0.58%). Additionally, the frequency of the A and G alleles in Iranians was 6.83 and 93.16%, respectively. Conclusion: The identification of the UGT1A1*6 alleles is necessary among the different Iranian ethnic groups before irinotecan therapy, suggesting that genotyping would be helpful for clinicians to optimize chemotherapy or identify individuals at risk of adverse drug reactions before clinical trials.Keywords
This publication has 15 references indexed in Scilit:
- Distribution of selected gene polymorphisms of UGT1A1 in a Saudi populationArchives of Medical Science, 2013
- Prospective Phase II Study of FOLFIRI for mCRC in Japan, Including the Analysis of UGT1A1*28/*6 PolymorphismsJapanese Journal of Clinical Oncology, 2011
- Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and PharmacokineticsJournal of Clinical Oncology, 2009
- UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patientsInternational Journal of Clinical Oncology, 2009
- Clinical Significance of UDP-Glucuronosyltransferase 1A1*6 for Toxicities of Combination Chemotherapy with Irinotecan and Cisplatin in Gynecologic CancersOncology, 2009
- Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan‐induced neutropenia in Asian cancer patientsCancer Science, 2007
- Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancerOncogene, 2006
- RACIAL VARIABILITY IN HAPLOTYPE FREQUENCIES OF UGT1A1 AND GLUCURONIDATION ACTIVITY OF A NOVEL SINGLE NUCLEOTIDE POLYMORPHISM 686C> T (P229L) FOUND IN AN AFRICAN-AMERICANDrug Metabolism and Disposition, 2005
- Identification of Defect in the Genes for Bilirubin UDP-Glucuronosyltransferase in a Patient with Crigler-Najjar Syndrome Type IIBiochemical and Biophysical Research Communications, 1993
- Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 1991